Portfolio intelligence
Find priorities across facilities. Follow the evidence into an investment decision, then review spending and service outcomes together.
Open dashboard demoTurn fragmented healthcare data into knowledge you can act on. See where care needs attention, make informed investments and follow the results.
Explore our interactive prototypes with illustrative data.

The platform
Healthcare records live in many places. Vezanta is designed to turn those separate sources into reusable data and metrics, ready for the applications your organisation needs.
Exports, spreadsheets, documents and existing APIs.
Raw sources with their history, provenance and access rules.
Transform, validate, calculate and model for different needs.
Give each application the data and results it is permitted to use.
New analyses and applications on the same foundation.
The platform is the product. Connecting new sources and building solutions on top is the service.
Two first applications
Different experiences, connected by a common purpose: understanding what needs to improve and whether a decision made a difference.
Find priorities across facilities. Follow the evidence into an investment decision, then review spending and service outcomes together.
Open dashboard demoShare what happened during a visit and add relevant medical context voluntarily. Help an authorised team understand the patient’s side of the story.
Open patient demoOur approach
We start with a focused pilot and clear questions. The aim is to make each new facility and each new application easier to connect.
A signal leads to supporting records, an investment decision and a follow-up. The owner can see what changed and investigate why.
Access follows the role and purpose. Owners receive aggregate signals. Authorised teams review specific cases with appropriate safeguards.
Start with our applications and services. Extend the platform with new solutions, and later with applications developed by partners.
Follow an illustrative case from a rising waiting time to an investment and its 90-day review.